Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.

Name: Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
Author: Roussel, Ronan

Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study. — المؤلف: Roussel, Ronan — Diabetes, obesity & metabolism 20200907

المؤلف: Roussel, Ronan
النشر: Diabetes, obesity & metabolism 20200907
الوصف: 781-790 p.
الموضوعات: Aged؛ Deprescriptions؛ Diabetes Mellitus, Type 2؛ Dipeptidyl-Peptidase IV Inhibitors؛ Double-Blind Method؛ Drug Therapy, Combination؛ Female؛ Glycated Hemoglobin